Cefuroxime
Cefuroxime (cefuroxime) is a small molecule pharmaceutical. Cefuroxime was first approved as Zinacef on 1983-10-19. It is used to treat bacterial infections, bacterial meningitis, bacterial pneumonia, escherichia coli infections, and gonorrhea amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cefuroxime (discontinued: Cefuroxime, Kefurox, Zinacef)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefuroxime sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER | B. Braun Medical | N-050780 DISCN | 2001-02-21 | 2 products, RLD |
| ZINACEF | PAI Pharma | N-050558 DISCN | 1983-10-19 | 3 products, RLD |
| ZINACEF IN PLASTIC CONTAINER | PAI Pharma | N-050643 DISCN | 1989-04-28 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefuroxime | ANDA | 2022-02-16 |
| cefuroxime and dextrose | New Drug Application | 2020-12-05 |
| cefuroxime axetil | ANDA | 2025-09-24 |
| cefuroxime axetil for oral suspension | ANDA | 2013-08-19 |
| cefuroxime sodium | ANDA | 2025-02-04 |
Indications
FDA
EMA
Show 6 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DC: Second-generation cephalosporins
— J01DC02: Cefuroxime
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA03: Cefuroxime and metronidazole
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA27: Cefuroxime
HCPCS
Code | Description |
|---|---|
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg |
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 3 | 1 | 8 | 10 | 22 |
| Surgical wound infection | D013530 | — | — | — | 2 | 2 | 8 | — | 12 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 2 | 6 | 9 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | 1 | 1 | 1 | 5 | 8 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | — | — | 2 | 4 | 7 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 2 | 2 | 2 | 6 |
| Wound infection | D014946 | — | — | — | 1 | 1 | 3 | 1 | 5 |
| Bacterial infections | D001424 | — | A49 | 1 | — | — | 1 | 3 | 5 |
| Postoperative complications | D011183 | — | — | — | — | — | 5 | — | 5 |
| Respiratory tract infections | D012141 | — | J06.9 | 1 | 1 | 2 | 1 | — | 4 |
Show 42 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | — | 1 | — | 1 | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 2 | — | — | 2 |
| Enterobacteriaceae infections | D004756 | EFO_1001313 | — | — | — | 1 | — | — | 1 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 1 | — | — | 1 |
| Bronchial diseases | D001982 | — | — | — | — | 1 | — | — | 1 |
| Emergencies | D004630 | — | — | — | 1 | 1 | — | — | 1 |
| Peptic ulcer | D010437 | — | K27 | — | — | 1 | — | — | 1 |
| Intestinal obstruction | D007415 | — | K56.60 | — | — | 1 | — | — | 1 |
| Peptic ulcer perforation | D010439 | EFO_1001389 | — | — | — | 1 | — | — | 1 |
| Otitis | D010031 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endophthalmitis | D009877 | — | — | 1 | 1 | — | — | 2 | 3 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | 1 | 2 |
| Rhinosinusitis | D000096825 | — | — | — | 1 | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Abscess | D000038 | EFO_0003030 | — | — | 1 | — | — | — | 1 |
| Abdominal abscess | D018784 | EFO_1001753 | — | — | 1 | — | — | — | 1 |
| Anaphylaxis | D000707 | — | T78.2 | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Drug hypersensitivity | D004342 | EFO_0009482 | T88.7 | — | 1 | — | — | — | 1 |
| Cephalosporin resistance | D018550 | — | Z16.19 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Chinese traditional medicine | D008516 | — | — | 1 | — | — | — | — | 1 |
| Rotator cuff injuries | D000070636 | — | M75.1 | 1 | — | — | — | — | 1 |
| Rotator cuff tear arthropathy | D000070656 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute cholecystitis | D041881 | EFO_1001289 | K81.0 | — | — | — | — | 3 | 3 |
| Cholecystitis | D002764 | — | K81 | — | — | — | — | 3 | 3 |
| Acalculous cholecystitis | D042101 | EFO_1000790 | — | — | — | — | — | 2 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 2 | 2 |
| Replacement arthroplasty hip | D019644 | — | — | — | — | — | — | 2 | 2 |
| Pharyngitis | D010612 | — | R07.0 | — | — | — | — | 1 | 1 |
| Mycoplasma pneumonia | D011019 | EFO_0007387 | J15.7 | — | — | — | — | 1 | 1 |
| Mycoplasma infections | D009175 | — | — | — | — | — | — | 1 | 1 |
| Pleuropneumonia | D011001 | — | — | — | — | — | — | 1 | 1 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefuroxime |
| INN | cefuroxime |
| Description | (6R,7R)-3-(carbamoyloxymethyl)-7-[[2-(2-furanyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid is a carbamate ester and a cephalosporin. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1 |
Identifiers
| PDB | — |
| CAS-ID | 55268-75-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1436 |
| ChEBI ID | 3515 |
| PubChem CID | 5361202 |
| DrugBank | DB01112 |
| UNII ID | O1R9FJ93ED (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cefuroxime
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 21,016 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,452 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use